Login to Your Account



Clinic Roundup


Friday, May 27, 2011
Pharmasset Inc., of Princeton, N.J., initiated a Phase IIa trial of nucleotide polymerase inhibitor PSI-7977 combined with Bristol-Myers Squibb Co.'s NS5A replication complex inhibitor BMS-790052 for hepatitis C. The trial will enroll 84 treatment-naïve patients, and four dosing groups will give the two drugs without standard-of-care ribavirin and pegylated interferon, while two dosing groups will add ribavirin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription